Article Venetoclax approved to treat CLL patients regardless of genotype Author: Edited by Jame Abraham; report by Jane de Lartigue Read More
Article Nivolumab and ipilimumab combination promises new standard of care for advanced RCC Author: Edited by Jame Abraham; report by Jane de Lartigue Read More
Article Neratinib extends adjuvant treatment of patients with HER2-positive breast cancer Author: Edited by Jame Abraham; report by Jane de Lartigue Read More
Article More biosimilars reach the market in efforts to improve access and cut costs Author: Edited by Jame Abraham; report by Jane de Lartigue Read More
Article First CAR T-cell therapy approvals bolster booming immunotherapy market Author: Edited by Jame Abraham; report by Jane de Lartigue Read More
Article Lenalidomide becomes standard of care for multiple myeloma in the maintenance setting Author: Edited by Jame Abraham; report by Jane de Lartigue Read More
Article Trastuzumab-dkst approval adds to the biosimilar cancer drug market Author: Edited by Jame Abraham; report by Jane de Lartigue Read More
Article Pembrolizumab for dMMR/MSI-H tumors marks first tumor agnostic FDA approval Author: Edited by Jame Abraham; report by Jane de Lartigue Read More
Article Brigatinib approval yields additional treatment options for crizotinib-resistant, ALK-positive NSCLC patients Author: Edited by Jame Abraham; report by Jane de Lartigue Read More
Article PD-L1-targeting drug atezolizumab nabs approval for non-small cell lung cancer Author: Edited by Jame Abraham; report by Jane de Lartigue Read More
Article Elotuzumab and ixazomib join the therapeutic arsenal for multiple myeloma Author: Edited by Jame Abraham; report by Jane de Lartigue Read More
